CBD is emerging as a promising pharmaceutical agent for treating pain, inflammation, seizures and anxiety without the psychoactive effects of THC. Studies have shown that CBD, often together with THC, is an effective pain reliever for various chronic diseases. In clinical trials, Sativex, an aerosol containing equal parts of CBD and THC, was found to be a significant pain reliever for cancer-related pain. Our understanding of the role of CBD in treating pain continues to evolve, and evidence from animal studies has demonstrated that CBD exerts its analgesic effects through its various interactions and the modulation of the endocannabinoid, inflammatory and nociceptive systems (pain detection).The endocannabinoid system consists of cannabinoid receptors that interact with our own natural cannabinoids.
This system is involved in the regulation of many body functions, such as metabolism and appetite, mood and anxiety, and the perception of pain. CBD doesn't bind very well to endocannabinoid receptors. However, a study in mice found that it can interact with neurological receptors in the spinal cord, which suppress chronic inflammatory pain. CBD may also enhance the effects of AEA, an endogenous cannabinoid that reduces pain. Cannabidiol (CBD), the main non-psychoactive component of Cannabis sativa L., has been clinically proven to provide therapeutic benefits in certain forms of epilepsy and imparts analgesia in certain conditions and improves quality of life.
CBD is still listed in Schedule I or V of the U. S. Drug Enforcement Agency's list of controlled substances. However, preparations labeled as CBD are available to the public in stores and on the streets. But using CBD doesn't always resolve pain.
Freely purchased CBD involves the risk of adulteration by potentially hazardous chemicals. In addition, the consumption of CBD by pregnant women is increasing and represents a major health hazard for future generations. In this mini-review, we present balanced and unbiased preclinical and clinical findings on the beneficial effects of CBD treatment on chronic pain and its deleterious effects on prenatal development. Given its promising results in animal models, along with its relative safety, its non-psychoactive properties and its low potential for abuse, CBD is an attractive candidate for pain relief. However, most human studies have investigated the role of CBD in treating cancer-related pain and treating cancer. People can add a few drops of CBD oil to food or drink or place a few drops under their tongue, where they can hold the oil for up to 1 minute before swallowing it. Also, keep in mind that the FDA has not approved over-the-counter CBD products and that some products may be incorrectly labeled.
As early as 2003, formulations containing CBD were used in the clinic to study their effectiveness in reducing pain when traditional treatment options have failed. There is a wide range of CBD products, including oils, tinctures, balms and candies, all of which can help people suffering from physical pain. Here we will summarize the conclusions of animal and human studies on some possible effects of CBD before, perinatal and postnatal. Keep in mind that THC, which is found in several CBD products, can have the opposite effect and product labels aren't always accurate. Some people with chronic pain use topical CBD products, in particular CBD oil, to control their symptoms. Until now, pharmaceutical CBD is only approved by the FDA as an adjunctive therapy for the treatment of a special and rare form of epilepsy. The increase in the prevalence of the non-psychoactive cannabinoid CBD presents an opportunity for the treatment of chronic intractable pain, for which primary treatments are insufficient or not possible.
Currently available studies are based on in vitro and rodent models but suggest molecular pathways that can be used to improve clinical use of CBD or offer alternative approaches to increase efficacy.
